| 张银铃,徐 伟,刁航航,田莹莹,杨洪霞.血清P53和Wip1水平与小细胞肺癌患者化疗疗效及预后的关系研究[J].现代生物医学进展英文版,2023,(20):3935-3939. |
| 血清P53和Wip1水平与小细胞肺癌患者化疗疗效及预后的关系研究 |
| Relationship Study between Serum P53 and Wip1 Levels and Chemotherapy Efficacy and Prognosis in Patients with Small Cell Lung Cancer |
| Received:February 25, 2023 Revised:March 21, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.20.027 |
| 中文关键词: 小细胞肺癌 P53 Wip1 化疗疗效 预后 评估价值 |
| 英文关键词: Small cell lung cancer P53 Wip1 Chemotherapy efficacy Prognosis Evaluation value |
| 基金项目:山东省重大科技创新工程专项课题项目（2018SDKJ0404-3） |
|
| Hits: 490 |
| Download times: 248 |
| 中文摘要: |
| 摘要 目的：探讨血清P53和野生型p53诱导的磷酸酶1（Wip1）水平与小细胞肺癌（SCLC）患者化疗疗效及预后的关系。方法：选择2015年6月至2017年6月青岛大学附属青岛市中心医院收治的109例SCLC患者为SCLC组和95例健康体检志愿者为对照组。所有SCLC患者均接受EP方案（依托泊苷+顺铂）化疗至少2个周期，化疗前检测血清P53和Wip1水平，出院后对所有患者进行为期5年的随访。统计随访期间SCLC患者总生存（OS）情况。分析血清Wip1和P53水平与SCLC患者临床病理特征、化疗疗效以及预后的关系。结果：SCLC组血清P53水平低于对照组（P＜0.05），血清Wip1表达高于对照组（P＜0.05）。临床分期为广泛期、远处转移患者血清P53水平低于临床分期为局限期、无远处转移患者（P＜0.05），血清Wip1表达高于临床分期为局限期、无远处转移患者（P＜0.05）。无效组血清P53水平低于有效组（P＜0.05），血清Wip1表达高于有效组（P＜0.05）。低水平P53组、高表达Wip1组5年OS生存率低于高水平P53组和低表达Wip1组（P＜0.05）。多因素Cox回归分析显示化疗耐药、远处转移、高表达Wip1是SCLC患者预后不良的危险因素（P＜0.05），高水平P53是其保护因素（P＜0.05）。结论：SCLC患者血清P53水平降低，Wip1表达增高与化疗效果较差和不良预后有关，检测血清P53表达和Wip1水平有助于辅助评估SCLC化疗疗效和预后。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum P53 and wild-type p53 induced phosphatase 1 (Wip1) levels and chemotherapy efficacy and prognosis in patients with small cell lung cancer (SCLC). Methods: A total of 109 patients with SCLC (SCLC group) who were admitted to Qingdao Central Hospital Affiliated to Qingdao University from June 2015 to June 2017 and 95 healthy volunteers in outpatient physical examination were selected as the control group. All patients with SCLC received EP regimen (etoposide combined with cisplatin) chemotherapy for at least 2 cycles, serum P53 and Wip1 levels were detected before chemotherapy, and all patients were followed up for 5 years after discharge. Overall survival (OS) of patients with SCLC during follow-up was counted. The relationship between serum Wip1 and P53 levels and clinicopathological characteristics, chemotherapy efficacy and prognosis of patients with SCLC were analyzed. Results: The serum P53 level in the SCLC group was lower than that in the control group (P＜0.05), and the serum Wip1 expression was higher than that in the control group (P＜0.05). The serum P53 level in patients with extensive period clinical stage and distant metastasis were lower than that in patients with limited period clinical stage and no distant metastasis (P＜0.05), and the serum Wip1 expression was higher than that in patients with limited clinical stage and no distant metastasis (P＜0.05). The serum P53 level in the ineffective group was lower than that in the effective group (P＜0.05), and the serum Wip1 expression was higher than that in the effective group (P＜0.05). The 5-year OS survival rates of low level P53 group and high expression Wip1 group were lower than those of high level P53 group and low expression Wip1 group (P＜0.05). Multivariate Cox regression analysis showed that chemotherapy resistance, distant metastasis and high expression of Wip1 were risk factors for poor prognosis in patients with SCLC (P＜0.05), and high level of P53 was a protective factor (P＜0.05). Conclusion: The decrease of serum P53 level and the increase of Wip1 expression in patients with SCLC are related to poor chemotherapy efficacy and poor prognosis. Detection of serum P53 expression and Wip1 level is helpful to evaluate the chemotherapy efficacy and prognosis of SCLC. |
|
View Full Text
View/Add Comment Download reader |
| Close |
